These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 12183246)

  • 1. High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan.
    Teng LJ; Hsueh PR; Tsai JC; Liaw SJ; Ho SW; Luh KT
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2908-13. PubMed ID: 12183246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
    Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
    J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1993 Aug; 37(8):1649-54. PubMed ID: 8215278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in the susceptibility of Bacteroides fragilis group organisms to various antimicrobial agents 1979-1989.
    Betriu C; Cabronero C; Gomez M; Picazo JJ
    Eur J Clin Microbiol Infect Dis; 1992 Apr; 11(4):352-6. PubMed ID: 1396757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging resistance of anaerobic bacteria to antimicrobial agents in South Korea.
    Lee K; Chong Y; Jeong SH; Xu XS; Kwon OH
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S73-7. PubMed ID: 8953110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.
    Roh KH; Kim S; Kim CK; Yum JH; Kim MS; Yong D; Lee K; Kim JM; Chong Y
    Korean J Lab Med; 2009 Aug; 29(4):293-8. PubMed ID: 19726890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-resistance to beta-lactam-beta-lactamase inhibitor combinations and clindamycin among cefoxitin-resistant and cefoxitin-susceptible strains of the Bacteroides fragilis group.
    Aldridge KE
    Diagn Microbiol Infect Dis; 1993 Oct; 17(3):251-6. PubMed ID: 8112038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial Susceptibility Patterns of Anaerobic Bacterial Clinical Isolates From 2014 to 2016, Including Recently Named or Renamed Species.
    Byun JH; Kim M; Lee Y; Lee K; Chong Y
    Ann Lab Med; 2019 Mar; 39(2):190-199. PubMed ID: 30430782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Sensitivity of strict anaerobic bacteria to metronidazole, cefoxitin, and clindamycin].
    Dubreuil L; Derriennic M; Reynaud A; Devos J; Romond C; Courtieu A
    Pathol Biol (Paris); 1985 Nov; 33(9):899-903. PubMed ID: 3909082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the bactericidal activity of clindamycin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
    Stratton CW; Weeks LS; Aldridge KE
    Diagn Microbiol Infect Dis; 1991; 14(5):377-82. PubMed ID: 1797454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
    Stratton CW; Weeks LS; Aldridge KE
    Diagn Microbiol Infect Dis; 1992; 15(4):321-30. PubMed ID: 1611847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
    Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
    Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Geographic patterns of antimicrobial susceptibilities for Bacteroides spp. worldwide: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2007-2020.
    Wu PH; Chen CH; Lin HH; Tseng KH; Ko WC; Ho MW; Hsueh PR
    Int J Antimicrob Agents; 2023 Jul; 62(1):106822. PubMed ID: 37088437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.
    Aldridge KE; Ashcraft D; Cambre K; Pierson CL; Jenkins SG; Rosenblatt JE
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1238-43. PubMed ID: 11257040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal study of susceptibilities of species of the Bacteroides fragilis group to five antimicrobial agents in three medical centers.
    Turgeon P; Turgeon V; Gourdeau M; Dubois J; Lamothe F
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2276-9. PubMed ID: 7840557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of susceptibility results of the Bacteroides fragilis group and other anaerobes by traditional MIC results and statistical methods.
    Aldridge KE; Johnson WD
    J Antimicrob Chemother; 1997 Mar; 39(3):319-24. PubMed ID: 9096180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of antimicrobial susceptibility in isolates of the Bacteroides fragilis group in Spain.
    García-Rodríguez JE; García-Sánchez JE
    Rev Infect Dis; 1990; 12 Suppl 2():S142-51. PubMed ID: 2305180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamins, penicillins, clindamycin, and metronidazole in the United States.
    Aldridge KE; Gelfand M; Reller LB; Ayers LW; Pierson CL; Schoenknecht F; Tilton RC; Wilkins J; Henderberg A; Schiro DD
    Diagn Microbiol Infect Dis; 1994 Apr; 18(4):235-41. PubMed ID: 7924220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro susceptibilities of species of the Bacteroides fragilis group to newer beta-lactam agents.
    Betriu C; Sánchez A; Gómez M; Palau ML; Picazo JJ
    J Antimicrob Chemother; 1999 Jan; 43(1):133-6. PubMed ID: 10381111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of anaerobic bacteria to antimicrobial agents.
    Collignon PJ; Munro R; Morris G
    Pathology; 1988 Jan; 20(1):48-52. PubMed ID: 3374973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.